(IN BRIEF) GSK has entered into a multi-programme development and licensing agreement with Hengrui Pharma to advance up to 12 innovative therapies, including HRS-9821, a potentially best-in-class PDE3/4 inhibitor currently in clinical trials for COPD. The deal includes $500 million … Read the full press release
Posted in Business, Financial, Government, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged AI-era medicine, biopharma partnership, Chronic obstructive pulmonary disease, clinical development, cloud healthcare, COPD treatment, drug innovation, drug pipeline, dry powder inhaler, Frank Jiang, global health, GSK, Hart-Scott-Rodino Act, Hengrui Pharma, HRS-9821, immunology, inflammation, licensing agreement, milestone payments, novel therapeutics, oncology, partnership, PDE3/4 inhibitor, pharmaceutical collaboration, phase I trials, respiratory medicine, Tony Wood
(IN BRIEF) Boehringer Ingelheim has entered into a multi-year collaboration with Cue Biopharma to develop and commercialize CUE-501, a first-in-class bispecific compound designed to selectively deplete harmful B cells in autoimmune diseases. The innovative therapy uses Cue’s Immuno-STAT™ platform to … Read the full press release
Posted in Business, Financial, Germany, Government, Healthcare, Investment, Management, News, Pharma & Biotech, Science, Technology
Tagged autoimmune diseases, B cell depletion, biologics innovation, biopharma collaboration, bispecific compound, Boehringer Ingelheim, Carine Boustany, chronic disease treatment, Cue Biopharma, CUE-501, Daniel Passeri, drug development, Immuno-STAT, Immuno-STAT platform, immunology pipeline, inflammatory diseases, licensing agreement, memory T cells, milestone payments, partnership, precision medicine, royalty payments, strategic partnership, T cell engagers, targeted biologics, up-front payment
Through this license agreement with Ablexis, Almirall is granted rights to use the AlivaMab® Mouse technology for research, development, and commercialisation of antibodies AlivaMab Mouse offers state-of-the-art transgenic mouse platforms delivering highdiversity human therapeutic antibodies Almirall will partner with AlivaMab … Read the full press release
Posted in Healthcare, News, Pharma & Biotech, Science, Spain, Technology
Tagged Ablexis, AlivaMab Discovery Services, AlivaMab Mouse, Almirall, antibody drug, antibody therapeutics, biopharmaceutical, dermatological conditions, Dr. Thomas Huber, human therapeutic antibodies, Justin Mika, Larry Green, licensing agreement, severe skin diseases, skin health
bloXmove is committed to designing cooperative mobility and promises seamless customer experiences in an integrated way. (PRESS RELEASE) STUTTGART, 31-May-2021 — /EuropaWire/ — Daimler Mobility AG announces licensing agreement with the mobility start-up bloXmove for its in-house developed Mobility Blockchain … Read the full press release
Posted in Automotive, Germany, Industrial, Infrastructure & Utilities, News, Technology
Tagged Blockchain Factory, blockchain technology, bloXmove, Carmen Roth-Schäfer, Daimler Mobility AG, decentralization, licensing agreement, Mobility Blockchain Platform, mobility infrastructure, mobility providers, mobility start-up, software, software license, Sophia Rödiger, urban mobility
Tampere, Finland, 31-Mar-2016 — /EuropaWire/ — Piceasoft and UK based Mobicode have signed a technology licensing agreement to integrate unique PiceaVolumeEraser™ as a part of Mobicode retail ‘ecosystem’. Mobicode considers PiceaEraser™ the best erasure tool in the market for their … Read the full press release
Posted in Business, News, Retail, Technology
Tagged cloud solutions, data erasure, data security, erasure software, independent retail chains, Jyri Roselius, licensing agreement, Mobicode, mobile erasure, mobile software, mobile technology, Peter Kirby, Piceasoft, PiceaVolumeEraser, retail, security software, software
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?